Money and Research

Regarding your FrontLines item, "The money-making academy,"1 at first I wondered if it was an April fool's joke, then I realized it was serious. This is an unsupported perpetuation of a myth promulgated by the research university establishment. What evidence is there that the commercial activities of universities have benefited society as a whole? Falling tuition costs? Cheaper drug prices? Reduced university budgets supported by fewer taxpayer dollars? I would argue that, in fact, all of the e

Written byMark Chao
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

I would argue that, in fact, all of the evidence clearly demonstrates the opposite effect. The increasing commercialization of university research activities has increased the cost to society as a whole. Universities are pressured to compete for top-dollar researchers, and to maintain state-of-the-art research facilities. The university license agreements generate royalties that are funneled back into the research activities. Companies paying royalties on such licenses merely pass on the cost to the consumer/taxpayer by way of higher drug prices. And during this entire process, both universities and companies can plead innocent as to the spiraling costs of research.

It is a sham, designed to perpetuate the inflated costs of research and the huge support/regulatory system in place to encourage it. If universities truly wanted to benefit society by their research discoveries, they would dedicate their discoveries, sponsored by the public funds, to the public for all to use equally, and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies